← Back to patent-cliff list
GDC-3280
Tier C — Watch / tradeGDC-3280
Genentech
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TGF-β, LPA
Indications (approved)：Idiopathic pulmonary fibrosis, 瘢痕, 皮肤增生性瘢痕
Regional status
US
Phase II
2026-02-11
EU
No progress
2015-06-01
China
Phase III
2026-07-21
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of GDC-3280?
Approved indications include: Idiopathic pulmonary fibrosis, 瘢痕, 皮肤增生性瘢痕.
When does the GDC-3280 patent expire?
No public expiry year is available for GDC-3280 yet; this page updates once verified.
How do I get a quote for GDC-3280 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29